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Predicting Cardiac
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by QRS Duration
The Long and Short of It*
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Baltimore, Maryland
As its name implies, cardiac resynchronization therapy
(CRT) attempts to restore contractile coordination in hearts
burdened by wall motion dyssynchrony due to conduction
delay. This is achieved by stimulating the region of the
ventricle with the most delayed mechanical activation so it
can contract in synchrony with the earlier stimulated terri-
tory. To further assure synchrony, CRT generally employs
two leads—one on the left ventricle (LV) and one on the
right, pacing both simultaneously or with a small delay
between them. Both acute and chronic studies have dem-
onstrated that restoring synchrony of contraction is benefi-
cial to the heart’s performance and energetics, to patient
exercise capacity and clinical well being, and to mortality
from heart failure (1–7).
See pages 2109 and 2117
One of the most critical questions to emerge from the
recent clinical trial data is how should one best target this
therapy; CRT devices are complex, invasive, and expensive.
Repeatedly, the percentage of non-responding patients as
indexed by clinical symptoms or objective evidence of the
absence of reverse chamber remodeling is 25% to 30% of
recipients. The major entry criteria to date have been the
presence of severe dilated heart failure (New York Heart
Association functional class III to IV), sinus rhythm, and
evidence of a conduction delay on the electrocardiogram as
reflected by widening of the QRS complex. Different studies
have used entry thresholds for QRS duration ranging from
150 in the MUltisite STimulation In Cardiomyopathy
(MUSTIC) trial (5), to 120 ms in the recently completed
COmparison of Medical therapy, PAciNg, and defibrilla-
tION in Chronic Heart Failure (COMPANION) trial. But
what is the evidence that QRS duration identifies the right
candidates?
Many acute studies have shown that the width of the
QRS complex is a general correlate of mechanical response
to CRT (8). This makes intuitive sense, because the level of
dyssynchrony should, to some extent, be reflected in the
spatially distributed electrical activation and, thus, electro-
cardiogram complex width. However, even under optimally
controlled conditions, the correlation between QRS dura-
tion and acute response is modest—with r2 values of 0.6,
thus explaining only about 30% to 40% of the variability in
contractile response to CRT. More importantly, many
chronic studies have now tested the correlation between
QRS duration and long-term clinical response. The latter
has been assessed largely by echo-Doppler–derived objec-
tive measures of chamber function or reverse-remodeling,
rather than by clinical symptoms. In general, QRS duration
has been a poor predictor of the CRT response (9–11). This
has been true in the larger placebo-controlled trials such as
Multicenter Insync RAndomized CLinical Evaluation
(MIRACLE), as well (6). Part of the issue lies in how the
analysis is itself performed, that is, regression of specific
outcomes against baseline QRS duration as a continuous
variable, as opposed to subdividing groups into narrower
(120 to 150 ms) or wider 150 ms QRS durations. But a
great deal of the problem with QRS duration is that it
simply does not consistently reflect the underlying level of
mechanical dyssynchrony, whereas the latter increasingly
appears to be most important (9,12–14).
Recent studies have demonstrated that, unlike QRS
duration, the magnitude of basal mechanical dyssynchrony
assessed by echocardiography or by tissue Doppler (velocity
mapping) is a better predictor of outcome. Three-
dimensional dyssynchrony assessed by magnetic resonance-
tagged imaging was first shown to best correlate with acute
mechanical benefit (8). One problem with QRS duration is
that it incorporates total ventricular activation (right and
left), and rapid right ventricular (RV) activation can be
offset by delayed LV activation to yield a normal-range
QRS despite considerable mechanical dyssynchrony. QRS
widening can, in turn, reflect more diffuse conduction
abnormalities or predominantly RV delays, but not belie
physiologically significant LV intraventricular delay.
One of the implications of the lack of a consistent
relationship between QRS duration and CRT response is
that patients could well exist with narrow QRS durations
yet significant mechanical dyssynchrony. Such patients
would not have qualified for entry into any of the prior
clinical CRT trials, yet, on the basis of recent data, might
well be predicted to benefit from CRT. This hypothesis was
tested by Achilli et al. (15) as reported in this issue of the
Journal. In this study of 52 patients, 14 of them had QRS
durations 120 ms, while the others had longer durations.
Both groups had a similar magnitude of mechanical dyssyn-
chrony based on wall motion/Doppler flow timing analysis.
All patients received standard biventricular CRT, and were
followed for a mean of one and a half years, with functional
assessments made after six months. The investigators found
remarkably similar clinical improvement in both groups,
reduced cardiac volumes and mitral regurgitation area, and
exercise capacity (6-min walk test). Basal intraventricular
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dyssynchrony did not correlate with reverse remodeling,
whereas there was a weak, but significant, correlation to
interventricular (RV to LV) dyssynchrony. This may reflect
differences in the signal/noise levels for these measurements.
There was no significant difference in these relations be-
tween the two group relations, but the correlation was not
significant in the narrow QRS group, likely, in part, due to
the smaller sample size and to reduced variance in the
independent variable.
There are some caveats to this study. First, it was not
performed in a placebo-controlled or blinded fashion, al-
though echocardiographic analysis was performed by inde-
pendent observers. Secondly, patients with both existing
pacemaker-induced QRS widening and those with intrinsic
conduction delay were combined. While the analysis failed
to reveal any significant difference between groups, the study
was not adequately powered to discern this. Given these
limitations, the study sends an intriguing and important
message: narrow QRS complex patients exist who benefit
from CRT so long as they have dyssynchronous contraction
of the LV. It further confirms that analysis of mechanical
dyssynchrony is better than QRS duration for predicting
this response.
Results of the PATH-CHF II study also reported in this
issue of the Journal by Auricchio et al. (16) appear on the
surface to be at odds with this conclusion, but, in reality, are
not. These investigators performed a placebo-controlled
crossover study of LV-only CRT. Mechanical dyssynchrony
was not reported, and inclusion into the study followed
standard criteria as previously used by most CRT trials. The
authors raised the prospective hypothesis that QRS duration
would stratify responders, and recruited equal numbers of
subjects with wide complexes (150 ms) and narrower ones
(120 QRS 150 ms). Of 86 subjects who received CRT
implantation, most received a surgically implanted epicar-
dial lead, with only 25 subjects receiving transvenous LV
pacing by a coronary vein. Of these subjects, 69 completed
the cross-over protocol. For the total group, LV-only pacing
resulted in significant improvement in exercise performance
and clinical symptoms, with positive changes correlating
with the three-month period of active therapy. However,
when the two subgroups were examined, only the patients in
the wide QRS group showed benefits; the patients with a
narrower QRS (still well within the range used in most
clinical CRT trials) did not demonstrate benefits from
CRT. As in prior trials, a placebo effect was observed in the
quality-of-life questionnaire, as even during the inactive
pacing period, quality-of-life score declined (i.e., improved
symptoms) compared with baseline.
This study confirms the notion that having a particularly
wide QRS complex means a greater likelihood of mechan-
ical delay and, thus, CRT benefit. However, one should not
conclude that having a QRS duration below 150 ms
precludes CRT utility, as this has clearly not been demon-
strated in the large-scale randomized trials such as MIRA-
CLE or COMPANION. The pacing mode (i.e., LV-only
vs. biventricular) may explain some of this difference, as LV
pacing may indeed work more optimally in patients with
very prolonged conduction delay times. Furthermore, this
study does not reject the hypothesis that QRS by itself is
adequate to optimally identify responders. Individual regres-
sion analysis was not presented, and one would not be
surprised to discover considerable scatter with some re-
sponders in the narrower QRS group and nonresponders in
the wide QRS group.
Finally, the study by Auricchio et al. (16) provides the
largest chronic placebo-controlled data dealing with LV
pacing, addressing the question whether two leads (biven-
tricular) are really required for effective chronic CRT. Early
acute studies demonstrated that both modes of pacing
enhance systolic function and energetic efficiency very sim-
ilarly, with, if anything, a slight advantage going to LV-only
pacing (4,8,17,18). Blanc et al. (19) subsequently reported
that LV-only CRT achieves similar chronic effects to that
with biventricular stimulation.
The mechanisms by which LV-only pacing works remain
somewhat controversial. While it was first supposed that
intrinsic conduction via the functional right branch fused
with the premature LV stimulation, animal and clinical
studies in atrial fibrillation patients have refuted this theory
(20). Rather, it appears that having early activation of the
lateral wall is itself sufficient to offset the major mechanical
deficits posed by left bundle branch block-type conduction
delay. One study that has suggested otherwise is from
Sogaard et al. (21), who reported that biventricular pacing
with the LV being activated well in advance of the RV
diminished CRT efficacy. This is at odds with the data
using LV-only pacing, because this is the ultimate case of
premature LV pacing. Further studies examining RV-LV
delays are still needed to clarify this.
Should we be implementing CRT using LV-only pacing?
Certainly the mode is simpler than biventricular stimula-
tion, and could make use of traditional pacemakers. How-
ever, there is growing evidence supporting a role for internal
defibrillation in many of the same patients who are CRT
candidates, so this distinction becomes a bit more academic
in nature. The LV lead is also the more difficult one to
implant, so there are, unfortunately, no real savings in
procedural time or costs. Nonetheless, this study adds fuel
to the fire that either mode of treatment can work chroni-
cally.
As we advance in our understanding of the role of CRT
in heart failure therapy, developments in the instrumenta-
tion, implantation methods, and stratification of appropriate
candidates loom large as areas in need of clarification. QRS
duration gets us into the right ballpark, but to achieve more
consistent success, attention should be paid to the mechan-
ical substrate and analysis of chamber dyssynchrony. The
tools to do so exist, although none have, as yet, proven
optimal or broadly applicable. Some methods, such as
strain-rate tissue Doppler, are specific to equipment and
unavailable in many laboratories. There remains a major
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need to simplify the process and achieve a widely acceptable
parameter to better stratify patients. If we stick to those with
QRS durations exceeding 150 ms, we will achieve a higher
responder rate, but miss many responsive candidates. Hope-
fully, with a usable mechanical synchrony measure, we can
better select patients most likely to benefit.
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